Business
GlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research
GlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research.
About this update from American Diversified Holdings Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n GlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research\r\n \r\n \r\n\r\n\r\nGlucoGuard Receives $43 Million Enterprise Valuation From Prominent CFA Led Harbinger Research\r\n\r\n\r\n\r\nNewsfile Corp.\r\n\r\n\r\nNewsfile Corp\r\n\r\n\r\nADHC Files July 31st, 2025 Annual Disclosure\r\nDel Mar, California--(Newsfile Corp. - November 4, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTCID: ADHC).\r\nThe report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models.\r\nAs the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition.\r\nA main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels.\r\nTo access the research report, please visit the Harbinger Research website at:\r\n2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report\r\n\"Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of \"Death in Bed\", commented ADHC. \"Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature,\" concluded ADHC.\r\nKey Aspects of the Report\r\n\r\n 537mm Diabetic Patients Worldwide.\r\n 37 mm Diabetic Patients In the US.\r\n 3.7 Type 1 Diabetics in the US.\r\n 190k to 380K Potential Patients in ...